Zydus Cadila has received the Drug Controller General's approval to market its H1N1 (swine flu) vaccine.
Zydus Cadila, now becomes the first company to launch H1N1 (swine flu) vaccine in India under the brand name VaxiFlu-S. VaxiFlu-S will be marketed by Vaxxicure, a division of the group focusing on preventives.
The egg-based inactivated vaccine has been developed at the company's Vaccine Technology Centre in Ahmedabad.
VTC further plans to develop a wide spectrum of vaccines against bacterial, viral and protonoal infections.
The group also markets Vaccines for rabies and typhoid.
Zydus Cadila CMD Pankaj Patel, said, "By launching this vaccine, we would be better prepared with an affordable therapy and prevent further loss of lives to this infectious disease. The launch of Vaxi Flu-S gives thrust to our objective of emerging as a strong player in the area of preventives."